CRV's operating profit rose to 3.8 million euros in '24 – '25

Chief Financial Officer Egon Verheijden is satisfied with CRV's results for the 2024 – 2025 financial year, which ran from 1 September 2024 through 31 August 2025. Net revenue increased by more than 10 million euros to over 195 million euros and operating profit rose by approximately 8 million euros to 3.8 million euros. Despite a substantial tax charge, a positive net result was achieved. In line with internal agreements, no member benefit will be paid out this year.

Verheijden is particularly pleased with the result in CRV's home market. 'With a reorganisation plan, we are anticipating a smaller livestock population in the Netherlands and Flanders. This enabled us to realise significant cost savings already in the past financial year,' he explains. 'However, the expected decline in the livestock population did not materialise this year, and milk and meat prices were favourable. As a result, our turnover exceeded expectations, including increased sales of SiryX semen."

The bluetongue outbreak in the summer of 2024 also affected CRV. Verheijden views this with mixed feelings. 'The virus caused a great deal of hardship to our member farmers. At the same time, more inseminations were required to get cows pregnant.'

CRV's international subsidiaries performed in line with expectations during the past financial year. "Results in Germany and the Czech Republic remained consistently strong, and in New Zealand we achieved solid turnover growth of around 8 percent," says the CFO. "Our subsidiary in Brazil also achieved a favourable result this year, partly because our strategic plan is delivering the desired improvements there, and partly due to good meat and milk prices." CRV USA achieved an increase in turnover over the past year, although cost control remains a point of attention here, according to Verheijden. Because China closed its borders to foreign genetics, this market was no longer accessible for CRV. "In the development of new markets for our services and products, we have increased our focus over the past financial year, which has translated into improved results," Verheijden adds.

In the interest of its members, CRV continues to invest in innovation in genetics and new data solutions. This year will also see a step in the development of the technology for sexed sperm (Engender).

For 2025-2026, Verheijden foresees a financial year with two contrasting phases. 'In the first few months, turnover remained at a good level. However, with falling milk prices and rising costs for manure disposal in prospect, revenue will come under pressure in the coming months. Cost awareness remains a point of attention.'